TX-MOUSER-ELECTRONICS
24.1.2022 20:12:08 CET | Business Wire | Press release
Mouser Electronics , Inc., the New Product Introduction (NPI) leader™ empowering innovation, is excited to partner with the DRAGON / PENSKE AUTOSPORT team for the ABB Formula E FIA World Championship series’ eighth season, which kicks off with double-header races at Diriyah E-Prix on January 28 and 29. The fourth consecutive season-opener at Diriyah gives fans two exciting night races just outside Saudi Arabia’s capital of Riyadh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005567/en/
Mouser is partnering with the DRAGON / PENSKE AUTOSPORT team throughout the 2021–22 ABB FIA Formula E World Championship racing season, in collaboration with TTI, Inc . and valued manufacturers Molex and KYOCERA AVX . This is the eighth-straight year that Mouser and Molex have sponsored Formula E racing.
Driver Sérgio Sette Câmara returns to the team to helm the No. 7 Penske EV-5 car, while Formula 1 reserve driver Antonio Giovinazzi joins the team to take the wheel of the No. 6 car. The new season serves up 16 races, including stops in Jakarta, Vancouver, and Seoul, plus increased car power and new race qualifying formats.
“Mouser is thrilled to team up with Molex, TTI and KYOCERA AVX to partner with DRAGON / PENSKE AUTOSPORT for the eighth year in a row,” said Todd McAtee, Vice President, Americas Business Development for Mouser Electronics. “Formula E’s focus on developing and incorporating the latest in electric vehicle technology resonates with Mouser, our customers, and our fans and followers. We wish Sette Câmara, Giovinazzi, and the team the best this season!”
"TTI is pleased to team up with Mouser in supporting this exciting sport and its spotlight on sustainable automotive technologies of the future,” said Mike Morton, TTI Chief Executive Officer.
“This new chapter of Formula E promises to continue the evolution of this thrilling sport and serves as a powerful showcase for its electric future,” said Fred Bell, Vice President of Global Distribution for Molex. “Mouser and Molex have been proud supporters since the inception of Formula E, and we wish the DRAGON / PENSKE AUTOSPORT team a safe and successful season.”
“We’re delighted to collaborate with Mouser, Molex, and TTI in our partnership with the DRAGON / PENSKE AUTOSPORT Formula E racing team for another exciting season,” said Alex Schenkel, KYOCERA AVX’s Senior Vice President of Global Sales.
The Formula E series features cars that are powered solely by electricity and represent a vision for the future of the motor sports industry, serving as a framework for research and development around zero-emission motoring. The Gen2 cars offer a huge step forward in electric vehicle racing technology, with maximum power of 250 kW and speeds up to 280 km/h. Racing is all about speed and endurance, and racing partnerships are an innovative way for Mouser to communicate its performance-driven business model and promote the newest technologies from its manufacturer partners.
Fans can cast a vote for Sette Câmara and Giovinazzi in FANBOOST , which allows fans to play an active role in influencing the outcome of the race. FANBOOST gives fans the opportunity to vote for their favorite driver and award them an extra boost of power during the race. The five drivers with the most FANBOOST votes are awarded a significant burst of power, which they can deploy in a 5-second window during the second half of the race. FANBOOST voting for the Diriyah E-Prix opens January 25 and is available up to 15 minutes into the race.
To learn more, visit https://www.mouser.com/formula-e/ .
For more Mouser news, visit https://www.mouser.com/newsroom/ .
As a global authorized distributor, Mouser offers the world’s widest selection of the newest semiconductors and electronic components — in stock and ready to ship™. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each of its manufacturer partners. To help speed customers’ designs, Mouser’s website hosts an extensive library of technical resources, including a Technical Resource Center , along with product data sheets, supplier-specific reference designs, application notes, technical design information, engineering tools and other helpful information.
Engineers can stay abreast of today’s exciting product, technology and application news through Mouser’s complimentary e-newsletter. Mouser’s email news and reference subscriptions are customizable to the unique and changing project needs of customers and subscribers. No other distributor gives engineers this much customization and control over the information they receive. Learn about emerging technologies, product trends and more by signing up today at https://sub.info.mouser.com/subscriber .
About Mouser Electronics
Mouser Electronics, a Berkshire Hathaway company, is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 5 million products from over 1,200 manufacturer brands. Mouser offers 27 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 630,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/ .
Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005567/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom